Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00246623 | US Inhaled Insulin Dose Titration Study | PHASE3 | COMPLETED | 120 | — | — | Nov 1, 2005 | Mar 1, 2007 | Feb 8, 2008 | 16 | United States |
| Name | Type | Description |
|---|---|---|
| Exubera (inhaled insulin) | DRUG | - |
| 8-point glucose diary (to assess pre- and post prandial glucoses) | PROCEDURE | - |
| Meal Tolerance Test | PROCEDURE | - |
| 24-hour continuous glucose monitoring (at select sites) | PROCEDURE | - |
| Pulmonary Function Testing | PROCEDURE | - |
| Hypoglycemic Event Monitoring | PROCEDURE | - |
| Laboratory Assessments | PROCEDURE | - |
| Nutritional Counseling and Diabetes Education | BEHAVIORAL | - |
Inclusion Criteria: * Male and female, age \>= 18 years and \<= 80 years, with a diagnosis of type 2 diabetes made at least 6 months prior to study entry, with hemoglobin A1C 7.5-10% * Currently treated with 2 or more oral antidiabetic agents (sulfonylureas, metformin, and/or thiazolidinediones) E...